The treatment with pasireotide in Cushing's disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center

What Was Tested

This randomized controlled trial paper looks at Somatostatin and Pasireotide.

Pasireotide is the first medical therapy officially approved for adult patients with Cushing's disease (CD) experiencing failure of pituitary surgery or not candidates for surgery.

The current study aimed at investigating pasireotide effects on clinical picture and metabolic profile in patients enrolled in the phase III CSOM230B2305 trial at Naples center.

Who Took Part

The abstract describes 14 patients taking part.

PubMed indexes the participants as adults, both men and women.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Somatostatin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

What Was Measured

The subject headings attached to it are Biomarkers, Blood Glucose, Drug-Related Side Effects and Adverse Reactions, Hormones, Lipids, Metabolome and Pituitary ACTH Hypersecretion.

Author keywords: Clinical picture, Cushing’s disease, Management of adverse events, Metabolic syndrome and Pasireotide.

What This Means in Plain Language

The paper is a randomized study of Somatostatin and Pasireotide in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2020 (Journal of endocrinological investigation), a journal based in Italy.

More context: the Somatostatin compound page and the Pasireotide compound page, all human trials.